Teva Pharmaceutical Industries (TEVA) Current Assets (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Current Assets came in at $13.8 billion in Q2 2026, up 9.03% YoY from $12.6 billion in Q2 2025, and little changed on a QoQ basis from $13.7 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Current Assets (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Current Assets data on file, last reported at $13.8 billion in Q2 2026.
- Quarterly Current Assets rose 9.03% year-over-year to $13.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.8 billion (up 9.03% YoY) and the FY2025 annual result came in at $13.9 billion, up 11.11% from the prior year.
- Current Assets was little changed at $13.8 billion in Q2 2026, from $13.7 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $13.9 billion in Q4 2025 to a low of $11.4 billion in Q3 2023.
- A 5-year average of $12.4 billion and a median of $12.3 billion in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets slipped 7.63% — and 2026, when it increased 18.93%.
- Tracing TEVA's Current Assets over 5 years: stood at $12.1 billion in 2022, then rose by 3.6% to $12.5 billion in 2023, then gained by 0.54% to $12.6 billion in 2024, then rose by 11.11% to $13.9 billion in 2025, then dropped by 1.33% to $13.8 billion in 2026.
- The last three Current Assets figures came in at $13.8 billion (Q2 2026), $13.7 billion (Q1 2026), and $13.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 3.22 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 1.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.76 Bn |
| Mar 31, 2026 | 13.71 Bn |
| Dec 31, 2025 | 13.95 Bn |
| Sep 30, 2025 | 12.74 Bn |
| Jun 30, 2025 | 12.62 Bn |
| Mar 31, 2025 | 11.53 Bn |
| Dec 31, 2024 | 12.55 Bn |
| Sep 30, 2024 | 12.31 Bn |
| Jun 30, 2024 | 11.63 Bn |
| Mar 31, 2024 | 12.30 Bn |
| Dec 31, 2023 | 12.49 Bn |
| Sep 30, 2023 | 11.43 Bn |
| Jun 30, 2023 | 12.09 Bn |
| Mar 31, 2023 | 11.50 Bn |
| Dec 31, 2022 | 12.05 Bn |
| Sep 30, 2022 | 11.45 Bn |
| Jun 30, 2022 | 12.16 Bn |
| Mar 31, 2022 | 12.45 Bn |
| Dec 31, 2021 | 12.57 Bn |
| Sep 30, 2021 | 12.15 Bn |